4.6 Review

Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes

期刊

LIFE-BASEL
卷 13, 期 6, 页码 -

出版社

MDPI
DOI: 10.3390/life13061291

关键词

pulmonary enteric carcinoma; colorectal cancer; immunochemistry; mutation analyses; colloid carcinoma; fetal carcinoma; NOS carcinoma

向作者/读者索取更多资源

Lung cancer is a common and deadly disease, with the 2021 WHO classification providing an updated categorization of lung adenocarcinomas and highlighting rare histological types. Rare variants of lung cancer are challenging to diagnose, but advances in mutational profiling and next-generation sequencing offer hope for better therapeutic options in the future. This review aims to summarize current knowledge on rare adenocarcinoma subtypes, providing clinicians with updated information to guide their practice.
Lung cancer is one of the most frequently diagnosed cancers worldwide and the leading cause of cancer-related death. The 2021 World Health Organization (WHO) classification provided a detailed and updated categorization of lung adenocarcinomas with a special focus on rare histological types, including enteric, fetal and colloid types, as well as not otherwise specified adenocarcinoma, overall accounting for about 5-10% of all cases. However, rare entities are nowadays difficult to diagnose in most centers, and evidence of optimal therapeutic management for these patients is still lacking. In recent years, increasing knowledge about the mutational profile of lung cancer, in addition to the spreading diffusion of next-generation sequencing (NGS) in different centers, have been helpful in the identification of rare variants of lung cancer. Hence, the hope is that several new drugs will be available in the near future to treat these rare lung tumors, such as in targeted therapy and immunotherapy, which are often used in clinical practice for several malignancies. The aim of this review is to summarize the current knowledge about the molecular pathology and clinical management of the most common rare adenocarcinoma subtypes in order to provide a concise and updated report that can drive clinicians' choices in their routine practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据